All In Biotech

NDA 017854 · Ani Pharms

Reglan

Metoclopramide Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

Dec 30, 1980

Approved uses

3

Original approval plus efficacy supplements

Registered trials

192

38 Phase 3, 6 recruiting

FAERS reports

77,180

69,461 serious, 9,975 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: TARDIVE DYSKINESIA Metoclopramide, including metoclopramide tablets, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including metoclopramide tablets, the risk of developing TD increases with duration of treatment and total cumulative dosage [see Warnings and Precautions ( 5.1 )] . Metoclopramide tablets are contraindicated in patients with a history of TD. Use metoclopramide tablets for the shortest duration of treatment and periodically reassess the need for continued treatment. Immediately discontinue metoclopramide tablets in patients who develop signs or symptoms of TD [see Warnings and Precautions ( 5.1 )] . In patients with symptomatic, documented gastroesophageal reflux, the maximum duration of metoclopramide tablets treatment is 12 weeks [see Dosage and Administration ( 2.1 ) and Warnings...

What it is approved for

From the label in effect Sep 16, 2026.

Metoclopramide Tablets USP are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use : Metoclopramide Tablets USP have not been shown to be safe and effective for the treatment of symptomatic, documented gastroesophageal reflux for longer than 12 weeks [see Warnings and Precautions ( 5.1 )] . Metoclopramide Tablets USP are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see Use in Specific Populations ( 8.4 )]. Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy ( 1 ) Relief of symptoms in adults with acute and recurrent diabetic gastroparesis ( 1 ) Limitations of Use: Metoclopramide tablets have not been shown to be safe and effective for the treatment of gastroesophageal reflux for longer than 12 weeks. ( 1 , 5.1 ) Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates ( 1 , 8.4 )

Mechanism: Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs. Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 15, 1984 Supplement 5 · Efficacy
  • Jun 28, 1982 Supplement 2 · Efficacy
  • Dec 30, 1980 Original approval · Type 3 - New Dosage Form
2 products under this application
  • REGLAN · METOCLOPRAMIDE HYDROCHLORIDE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
  • REGLAN · METOCLOPRAMIDE HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metoclopramide" as an intervention, any sponsor and status, largest first.

All 192 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • tardive dyskinesia16,216
  • extrapyramidal disorder12,921
  • nervous system disorder7,526
  • dystonia7,115
  • nausea6,547
  • pain5,998
  • vomiting4,989
  • diarrhoea4,164
  • anxiety4,091
  • economic problem3,962
  • incorrect drug administration duration3,710
  • fatigue3,614

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,145
20051,207
20061,167
20071,134
20081,315
20091,732
20102,835
201112,666
20127,303
20132,666
20142,319
20152,550
20162,948
20172,755
20183,701
20194,071
20203,888
20214,264
20224,266
20233,846
20243,498
20253,286
20262,601

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Reglan (Metoclopramide HCl)

2024 spending

$68K

Beneficiaries

33

122 claims

Per beneficiary

$2,051

$3.86 per unit

View as table
YearSpending
2020$106,782
2021$94,620
2022$88,032
2023$88,394
2024$67,698

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,551 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.